Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Can-Fite BioPharma completed enrollment of the first 247 patients, triggering the pre-specified interim analysis of its pivotal Phase 3 trial (NCT06643260) for piclidenoson, a first-in-class oral A3 adenosine receptor (A3AR) agonist, in moderate-to-severe plaque psoriasis
For IC 50 calculations with dengue virus, phenformin or atpenin A5 were prediluted in Huh7.5 complete media and added to Huh7.5 cells 1 h before adding the virus (MOI = 1)
Chin Med J
A long-term, randomized, double-blind, placebo-controlled study
World Journal of Gastroenterology, 17 , 38883898
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 21.41
US$ 28.75
US$ 25.23
:max_bytes(150000):strip_icc()/Ozempic-Changed-How-Much-People-Spend-on-Food-FT-BLOG0125-687f168f66fa4125be18ba5fcf629792.jpg)
